We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Special evolution in myelofibrosis – case reports.
- Authors
Iordan, Iuliana; Neculcea, Andreea; Mititelu, Alina; Popescu, Claudiu; Vlădăreanu, Ana Maria
- Abstract
Myelofibrosis is a chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by bone marrow fibrosis, inefficient hematopoiesis and extramedullary hematopoiesis. Since their approval in the treatment of myelofibrosis, JAK inhibitors had a positive impact, being the most effective treatment for improving symptomatology and spleen reduction. However, one should weight the benefits and the risks of this treatment, which include hematological toxicity, opportunistic infections, reactivation of latent infections, and an increased risk for chronic lymphoprolifera-tive disorders. We report two cases of myelofibrosis patients treated with a JAK2 inhibitor who developed non-Hodgkin lymphoma and tuberculosis, respectively.
- Subjects
MYELOFIBROSIS; EXTRAMEDULLARY hematopoiesis; LATENT infection; MYELOPROLIFERATIVE neoplasms; OPPORTUNISTIC infections; NON-Hodgkin's lymphoma
- Publication
Oncolog-Hematolog, 2022, Issue 61, p8
- ISSN
2066-8716
- Publication type
Article